Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03889444 · ClinicalTrials.gov registry record
Chart Review: Drug Utilization Study in Participants Who Received Ozurdex™ (Dexamethasone Intravitreal Implant) 0.7 mg Injections for Visual Impairment Due to Diabetic Macular Edema (DME)
A clinical trial, sponsored by Allergan.
- Completed
- Registry status
- 141
- Enrollment target
NCT03889444: Completed study, sponsored by Allergan.
NCT03889444 is a clinical trial that has completed, run by Allergan. The registered enrollment target is 141 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03889444 has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- 141 participants
- Enrollment target
Study Summary
A retrospective, non-interventional, observational, multi-center, drug utilization study to be conducted in adult participants with visual impairment due to DME treated with Ozurdex implants in Germany and Switzerland from 1 January 2015 to 1 September 2017.
Primary Outcome
Study eye was defined as the eye that received the most OZURDEX® injections.
Interventions
- DRUG Dexamethasone intravitreal implant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2019-01-15 |
| Est. Completion | 2019-06-07 |
What the finished NCT03889444 record still lists
NCT03889444 is an observational study that tracks outcomes without assigning an intervention. The registered 141 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Dexamethasone intravitreal implant is the first listed.
NCT03889444 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03889444 about?
NCT03889444 is a clinical study titled "Chart Review: Drug Utilization Study in Participants Who Received Ozurdex™ (Dexamethasone Intravitreal Implant) 0.7 mg Injections for Visual Impairment Due to Diabetic Macular Edema (DME)". A retrospective, non-interventional, observational, multi-center, drug utilization study to be conducted in adult participants with visual impairment due to DME treated with Ozurdex implants in Germany and Switzerland from 1 January 2015 to 1 September 2017.
What is the current status of trial NCT03889444?
This trial is currently completed. The enrollment target is 141 participants. The study started on 2019-01-15. Estimated completion is 2019-06-07.
What interventions are being tested in trial NCT03889444?
The interventions under investigation include: Dexamethasone intravitreal implant (DRUG).
Who is sponsoring clinical trial NCT03889444?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03042962 · 141 participants
Brain Networks in Dystonia
- NCT04378439 · 141 participants · NA
Appalachian Partnership to Reduce Disparities (Aim 2)
- NCT04775485 · 141 participants · Phase 2
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
- NCT05040360 · 141 participants · Phase 2
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI